In this way, future obesity treatments might look more like modern cancer care than traditional weight loss approaches, said Ashley Zehnder, PhD, Co-Founder and CEO of Fauna Bio
At TrimRx, our commitment to safety is paramount
At year 2, high-density lipoprotein cholesterol significantly increased with liraglutide 2.4/3.0 mg versus orlistat (treatment difference 0.07 mmol l 1 , P =0.03), and both low-density lipoprotein cholesterol and triglycerides decreased from randomization with liraglutide 2.4/3.0 mg (treatment difference 0.12 mmol l 1 for triglycerides, P =0.053 versus orlistat)
This substantial reduction can have a profound impact on obesity-related conditions, potentially reducing the need for certain medications and lowering the risk of cardiovascular diseases
DSIP promotes natural sleep architecture